Vimta Labs Limited - Asset Resilience Ratio

Latest as of September 2025: 15.99%

Vimta Labs Limited (VIMTALABS) has an Asset Resilience Ratio of 15.99% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Vimta Labs Limited carry for a breakdown of total debt and financial obligations.

Liquid Assets

Rs828.61 Million
≈ $8.96 Million USD Cash + Short-term Investments

Total Assets

Rs5.18 Billion
≈ $56.04 Million USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio Trend (2006–2025)

This chart shows how Vimta Labs Limited's Asset Resilience Ratio has changed over time. See net assets of Vimta Labs Limited for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Vimta Labs Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Vimta Labs Limited.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Rs545.38 Million 10.53%
Short-term Investments Rs283.23 Million 5.47%
Total Liquid Assets Rs828.61 Million 15.99%

Asset Resilience Insights

  • Good Liquidity Position: Vimta Labs Limited maintains a healthy 15.99% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Vimta Labs Limited Industry Peers by Asset Resilience Ratio

Compare Vimta Labs Limited's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Sonic Healthcare Ltd
AU:SHL
Diagnostics & Research 0.13%
Eurofins-Cerep SA
PA:ALECR
Diagnostics & Research 6.56%
Inoviq Ltd
AU:IIQ
Diagnostics & Research 56.29%
Bcal Diagnostics Ltd
AU:BDX
Diagnostics & Research 0.00%
Imagion Biosystems Ltd
AU:IBX
Diagnostics & Research 150.16%
Integral Diagnostics Ltd
AU:IDX
Diagnostics & Research 0.03%
Australian Clinical Labs Ltd
AU:ACL
Diagnostics & Research 4.11%
Monash Ivf Group Ltd
AU:MVF
Diagnostics & Research 1.60%

Annual Asset Resilience Ratio for Vimta Labs Limited (2006–2025)

The table below shows the annual Asset Resilience Ratio data for Vimta Labs Limited.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-03-31 3.62% Rs168.85 Million
≈ $1.83 Million
Rs4.67 Billion
≈ $50.45 Million
+0.58pp
2024-03-31 3.04% Rs121.60 Million
≈ $1.32 Million
Rs4.00 Billion
≈ $43.26 Million
+0.54pp
2023-03-31 2.50% Rs90.73 Million
≈ $981.21K
Rs3.62 Billion
≈ $39.18 Million
+2.37pp
2022-03-31 0.13% Rs4.06 Million
≈ $43.91K
Rs3.07 Billion
≈ $33.22 Million
-0.01pp
2021-03-31 0.14% Rs3.92 Million
≈ $42.39K
Rs2.74 Billion
≈ $29.67 Million
-0.24pp
2020-03-31 0.38% Rs9.32 Million
≈ $100.79K
Rs2.46 Billion
≈ $26.58 Million
+0.18pp
2019-03-31 0.20% Rs4.70 Million
≈ $50.83K
Rs2.37 Billion
≈ $25.68 Million
-0.85pp
2018-03-31 1.05% Rs24.39 Million
≈ $263.77K
Rs2.32 Billion
≈ $25.12 Million
+0.58pp
2017-03-31 0.47% Rs10.45 Million
≈ $113.01K
Rs2.22 Billion
≈ $23.97 Million
+0.38pp
2011-03-31 0.09% Rs1.58 Million
≈ $17.09K
Rs1.77 Billion
≈ $19.09 Million
-12.57pp
2007-03-31 12.66% Rs220.22 Million
≈ $2.38 Million
Rs1.74 Billion
≈ $18.81 Million
-28.47pp
2006-03-31 41.13% Rs702.53 Million
≈ $7.60 Million
Rs1.71 Billion
≈ $18.47 Million
--
pp = percentage points

About Vimta Labs Limited

NSE:VIMTALABS India Diagnostics & Research
Market Cap
$220.67 Million
Rs20.40 Billion INR
Market Cap Rank
#16155 Global
#808 in India
Share Price
Rs457.15
Change (1 day)
+1.46%
52-Week Range
Rs380.70 - Rs1071.90
All Time High
Rs1155.00
About

Vimta Labs Limited provides contract research and testing services in India and internationally. The company offers drug discovery, development, and drug life cycle management support services in the areas of preclinical research, clinical research, and analytical services for biopharmaceutical companies; preclinical research and testing services for medical device companies; and contract researc… Read more